CEACAM5 and medullary thyroid gland carcinoma: Patients with structurally residual MTC are categorized as having either stable or unstable disease, and those with stable disease should undergo active surveillance with monitoring of serum levels of Ctn and CEA with imaging by at least an ultrasound every 3–6 months [35,52].